Rotigotine Schwarz Pharma.
Schwarz Pharma AG, under license from Aderis Pharmaceuticals Inc, is developing rotigotine CDS, a once-daily transdermal patch formulation of rotigotine, which is a naphthol-derived selective D(2) dopamine agonist, for the potential treatment of Parkinson's disease and restless legs syndrome.
Mucke
Hermann A M
HA
HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria. office@hmpharmacon.com
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018491:Dopamine Agonists / Q000737:chemistry / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists; D012148:Restless Legs Syndrome / Q000188:drug therapy / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods*; D013764:Tetrahydronaphthalenes / Q000737:chemistry / Q000627:therapeutic use*; D013876:Thiophenes / Q000737:chemistry / Q000627:therapeutic use*
D018491:Dopamine Agonists; D015507:Drugs, Investigational; D017448:Receptors, Dopamine D2; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine